장마감
로그인 회원가입
TALK
TALK
Talkspace Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$5.22
+0.01 ▲ +0.19%
🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)
$5.21
-0.01 ▼ -0.19%

토크스페이스(TALK) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$874M
스몰캡
P/E
915.8
고평가 구간
배당수익률
없음
52주 위치
99%
저점 +135% · 고점 -1%
애널리스트
매수
B
Fundamental health
vs. Health Information Services
수익성
Top 36%
성장
Top 31%
밸류에이션
Top 13%
재무 안정
Top 46%
💰 Is this stock pricier than usual right now?
Compared to this company's own recent 2년 (not other companies).
Very cheap
Cheap
Typical
Pricey
🔥 Very pricey
Simply put — what you pay today to own $1 of this company's yearly earnings is 747원. Over the past 2년, it usually traded around 158원. Earnings have also shrunk, which lifts the multiple — one of the priciest stretches of the past 2년.
Pricy doesn't mean bad — it means expectations are already baked in.· based on 1.6 profitable years
Index RUTP/E 915.79EPS (ttm) 0.01Insider Own 10.94%Shs Outstand 167.5MPerf Week 0.19%
Market Cap 0.87BForward P/E 26.43EPS next Y 52.75%Insider Trans -0.52%Shs Float 149.2MPerf Month 0.58%
Enterprise Value 0.79BPEG 0.28EPS next Q 0.03Inst Own 77.43%Short Float 2.48%Perf Quarter 0.77%
Income 0.00BP/S 3.67EPS this Y 223.25%Inst Trans 14.17%Short Ratio 1.93Perf Half Y 28.89%
Sales 0.24BP/B 7.73EPS next 5Y 95.74%ROA 0.86%Short Interest 3.71MPerf YTD 43.8%
Book/sh 0.67P/C 10.38EPS past 3/5Y -ROE 1.03%52W High -0.57% ($5.25)Perf Year 107.55%
Cash/sh 0.5P/FCF -Sales past 3/5Y 24.16% 24.61%ROIC 1.03%52W Low 135.14% ($2.22)Perf 3Y 207.06%
Dividend Est. -EV/EBITDA 908.28EPS Y/Y TTM -58.05%Gross Margin 40.61%Volatility(W/M) 0.21% 0.32%Perf 5Y -14%
Dividend TTM -EV/Sales 3.32Sales Y/Y TTM 22.64%Oper. Margin -1.21%ATR (14) 0.02Perf 10Y -
Dividend Ex-Date -Quick Ratio 4.84EPS Q/Q -2194.44%Profit Margin 0.49%RSI (14) 54.15Recom 2
Dividend Gr. 3/5Y -Current Ratio 4.84Sales Q/Q 18.2%SMA20 0.11% ($5.21)Beta 1.1Target Price $5.62
Payout -Debt/Eq 0Earnings 2026/05/05SMA50 0.23% ($5.21)Rel Volume 0.35Prev Close $5.21
Employees 598LT Debt/Eq 0EPS/Sales Surpr. -40.99% -1.34%SMA200 19.31% ($4.38)Avg Volume(3M) 1.92MPrice $5.22
IPO 2020/7/30Option/Short Yes/YesTrades 2340Volume 672,238Change 0.19%
Quarterly earnings trend SEC filings · USD
24.6
24.9
24.12*
25.3
25.6
25.9
25.12*
26.3
Revenue Net income 최근 분기: 매출 $62M (YoY +18%) · 순이익 $-6M (YoY -2083%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Talkspace Inc (TALK) Investment Analysis

What kind of company is Talkspace Inc?

토크스페이스(TALK) 초고성장주
Healthcare · Health Information Services
Healthcare Stocks

🧠 Talkspace is a US-based tele-behavioral health company that operates a virtual mental health platform built around chat, voice, and video. It connects users with licensed therapists and psychiatric providers, offering online counseling and medication management, and delivers its services through insurers, employers, and direct-to-consumer channels. The company is focused on lowering the barriers to mental health care by leveraging digital accessibility.

Learn more about Talkspace Inc →
Market Cap
$0.9B
Approx. KRW 1.2 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank2751
Employees598people
IPO2020/07/30
Current Price$5.22 ≈ 7,151원
📌 RUT · NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 5일 (화) · 장 마감 후 EPS -41.0% 매출 -1.3%
🔔 Earnings release 2026년 2월 19일 (목) · 장 시작 전 EPS +44.2% 매출 +1.7%

Is it profitable?

Financially sound but profitability is low
Losses or thin margins — early-stage growth or weakening competitiveness
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
-1.2%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Net Margin
Share of revenue left after taxes and interest are paid
0.5%
✓ 양호
My positionMid-range
Low range Average High range
Health Information Services 소형주 Median -0.9% · Top 38%
💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
40.6%
✓ 부진
My positionBottom 25%
Low range Average High range
Health Information Services 소형주 Median 55.0% · Bottom 19%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
1.0%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 소형주 Median -37.5% · Top 20%
💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)
ROA
Annual earnings relative to total company assets
0.9%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 소형주 Median -21.8% · Top 20%
💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수
ROIC
Return generated per dollar invested in the business
1.0%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 소형주 Median -25.0% · Top 20%
💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.00
✓ Very low debt
My positionTop 5%
Low range Average High range
Health Information Services Median 0.19
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
4.84
✓ 우수
My positionTop 25%
Low range Average High range
Health Information Services Median 1.76
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
4.84
✓ 우수
My positionTop 25%
Low range Average High range
Health Information Services Median 1.76
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$5.62
현재가 대비 +7.7%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
26.43배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
PEG (성장 반영 밸류)
0.28
저평가
💡 PEG < 1 — 성장 대비 저렴
내년 EPS 예상 성장률
+52.8%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+95.7%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility
Frequently misses analyst estimates
0
예상 상회
1
예상 부합
1
예상 하회
0%
상회 비율
-20.5%
평균 서프라이즈
2026.05.05
하회
-41.0%
2026.02.19
부합
실적 $0.03 · 예상 $0.03 +0.0%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Strong Growth
Above the industry average, both historically and going forward
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+223.3%
우수
My positionTop 25%
Low range Average High range
초고성장주 소형주 Median 51.6% · Top 10%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+52.8%
양호
My positionMid-range
Low range Average High range
초고성장주 소형주 Median 33.7% · Top 35%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+95.7%
우수
My positionTop 5%
Low range Average High range
초고성장주 소형주 Median 40.0% · Top 5%
📊 How much has it grown? (actual results)
Past 5-Year Revenue
How much revenue grew over the past 5 years
+24.6%
평균
My positionMid-range
Low range Average High range
초고성장주 소형주 Median 32.4% · Bottom 41%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+18.2%
양호
My positionMid-range
Low range Average High range
초고성장주 소형주 Median 14.5% · Top 47%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -82%p below the market
TALK -14.0% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-82.3%p
Significantly behind the market
vs Health Care (XLV)
-38.5%p
Significantly behind the sector average
1-year basis
vs S&P 500
+91.5%p
well ahead of the market
vs Health Care (XLV)
+87.8%p
well ahead of the sector average
Rank among peers
5-year return Top among peers Based on 14 peers
1-year return Top among peers Based on 16 peers
Current position within 52-week range
Low (-135.1%p) High (-0.6%p)
Current price is 135.1% above the 52-week low and 0.6% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-9.6%
Annualized volatility
37.3%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟡
Current diagnosis · 2026-07-27
Squeeze — volatility contraction, breakout imminent

Band width narrowed to 0.7%. Big move may be near. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-27
Neutral zone — weak trend

MACD 0.003 · Signal 0.004 · Hist -0.001. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢
Current diagnosis · 2026-07-27
Bullish zone

RSI 55.6 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 25.0.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry
Pricey on Vs. Earnings·Vs. Assets·Vs. Cash Flow, In line with peers on Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Pricey
🏢 Vs. Assets Pricey
🧾 Vs. Sales Mid-range
💧 Vs. Cash Flow Pricey
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
915.79x
✓ Very pricey
My positionBottom 5%
Low range Average High range
Health Information Services median 45.78x · Bottom 1% — expensive within the industry
💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
26.43x
✓ Pricey
My positionBottom 25%
Low range Average High range
Health Information Services median 18.57x · Bottom 25% — expensive within the industry
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
7.73x
✓ Pricey
My positionBottom 25%
Low range Average High range
Health Information Services 소형주 median 2.26x · Bottom 14% — expensive within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
3.67x
✓ Fair
My positionMid-range
Low range Average High range
Health Information Services 소형주 median 2.25x · Around the industry average
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
908.28x
✓ Very pricey
My positionBottom 5%
Low range Average High range
Health Information Services median 12.71x · Bottom 1% — expensive within the industry
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
Analyst target price (reference)
$5.62 vs. current price +7.7%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Health Information Services

Who owns it?

Ownership flow is positive
Insider modest net selling -0.5% · Institutional net buying +14.2% · Short interest light 2.5% · Short interest fell -1.8%p over the last 90 days
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-0.5%
Insiders net selling
🏦 Institutions (funds & investors)
+14.2%
Institutions large net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 77.4%
Adequate institutional weight
Healthcare 소형주 Median 65.6%
🧑‍💼 Insiders 10.9%
Founder/management large holders (strong skin-in-the-game)
Healthcare 소형주 Median 17.6%
👤 Retail investors (estimated) 11.6%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
2.5%
Low — limited short-side pressure
Healthcare 소형주 Median 11.2%
Past 90 days 📉 -1.8%p decrease
Short interest days to cover
1.9 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 167.5M주
Float (tradable shares) 149.2M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding TALK

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
TALK TALK This Stock
$874.4M915.8 7.7 1.03% - +0.2%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 토크스페이스(TALK)?

토크스페이스(TALK) belongs to the Healthcare sector and operates in the Health Information Services industry.

What is the market cap of TALK?

The market cap of TALK is approximately $874M, ranking 2,751 within its sector.

What is the P/E ratio of TALK?

TALK has a P/E ratio of approximately 915.8x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for TALK?

TALK has recorded a 52-week high of $5.25 and a low of $2.22.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.